Pretransplant donor and recipient CTLA-4 mRNA and protein levels as a prognostic marker for aGvHD in allogeneic hematopoietic stem cell transplantation

Immunology Letters

Volumn 165, Issue 1, 2015, Pages 52-59

  Karabon, Lidia ^a,b   Markiewicz, Miroslaw ^c   Kosmaczewska, Agata ^a   Partyka, Anna ^a   Pawlak Adamska, Edyta ^a   Tomkiewicz, Anna ^a   Ciszak, Lidia ^a   Jagoda, Krystyna ^c   Dzierzak Mietla, Monika ^c   Kyrcz Krzemien, Slawomira ^c   Frydecka, Irena ^a  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Acute graft vs host disease; CTLA 4; Hematopoietic stem cell transplantation; MRNA expression level; Protein expression level

Indexed keywords

BUSULFAN; CYCLOSPORIN A; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FLUDARABINE; MELPHALAN; MESSENGER RNA; METHOTREXATE; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOTRANSPLANTATION; ANEMIA; ARTICLE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOLOGICAL TOLERANCE; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; NONMYELOABLATIVE CONDITIONING; PATHOGENESIS; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; ACUTE DISEASE; ADVERSE EFFECTS; DONOR; GENE EXPRESSION; GENETICS; GRAFT RECIPIENT; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; METABOLISM; MIDDLE AGED; RECEIVER OPERATING CHARACTERISTIC; YOUNG ADULT;

ACUTE DISEASE; ADULT; CTLA-4 ANTIGEN; FEMALE; GENE EXPRESSION; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RNA, MESSENGER; ROC CURVE; TISSUE DONORS; TRANSPLANT RECIPIENTS; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84927557337     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2015.03.011     Document Type: Article

References (26)

1. Ferrara J.L. Advances in the clinical management of GVHD. Best Pract. Res. Clin. Haematol. 2008, 21:677-682.
2. Frauwirth K.A., Thompson C.B. Activation and inhibition of lymphocytes by costimulation. J. Clin. Invest. 2002, 109:295-299.
3. Walunas T.L., Lenschow D.J., Bakker C.Y., Linsley P.S., Freeman G.J., Green J.M., et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994, 1:405-413.
4. Valk E., Rudd C.E., Schneider H. CTLA-4 trafficking and surface expression. Trends Immunol. 2008, 29:272-279.
5. Li J., Semple K., Suh W.K., Liu C., Chen F., Blazar B.R., et al. Roles of CD28, CTLA4, and inducible costimulator in acute graft-versus-host disease in mice. Biol. Blood Marrow Transplant. 2011, 17:962-969.
6. Blazar B.R., Taylor P.A., Panoskaltsis-Mortari A., Sharpe A.H., Vallera D.A. Opposing roles of CD28:B7 and CTLA-4:B7 pathways in regulating in vivo alloresponses in murine recipients of MHC disparate T cells. J. Immunol. 1999, 162:6368-6377.
7. Yu X.Z., Albert M.H., Martin P.J., Anasetti C. CD28 ligation induces transplantation tolerance by IFN-gamma-dependent depletion of T cells that recognize alloantigens. J. Clin. Invest. 2004, 113:1624-1630.
8. Kurtz J., Raval F., Vallot C., Der J., Sykes M. CTLA-4 on alloreactive CD4 T cells interacts with recipient CD80/86 to promote tolerance. Blood 2009, 113:3475-3484.
9. Przepiorka D., Weisdorf D., Martin P., Klingemann H.G., Beatty P., Hows J., et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995, 15:825-828.
10. Kosmaczewska A., Bocko D., Ciszak L., Wlodarska-Polinska I., Kornafel J., Szteblich A., et al. Dysregulated expression of both the costimulatory CD28 and inhibitory CTLA-4 molecules in PB T cells of advanced cervical cancer patients suggests systemic immunosuppression related to disease progression. Pathol. Oncol. Res. 2012, 18:479-489.
11. Chomczynski P. A reagent for the single-step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples. Biotechniques 1993, 15:532-537.
12. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408.
13. Rousseeuw P.J., Croux C. Alternatives to the median absolute deviation. JASA 1993, 88:1273-1283.
14. Efron B. Bootstrap methods: another look at the jackknife. Ann. Statist. 1979, 7:1-26.
15. Fuji S., Kim S.W., Fukuda T., Mori S., Yamasaki S., Morita-Hoshi Y., et al. Preengraftment serum C-reactive protein (CRP) value may predict acute graft-versus-host disease and nonrelapse mortality after allogeneic hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 2008, 14:510-517.
16. Jordan W.J., Brookes P.A., Szydlo R.M., Goldman J.M., Lechler R.I., Ritter M.A. IL-13 production by donor T cells is prognostic of acute graft-versus-host disease following unrelated donor stem cell transplantation. Blood 2004, 103:717-724.
17. Magenau J.M., Qin X., Tawara I., Rogers C.E., Kitko C., Schlough M., et al. Frequency of CD4(+)CD25(hi)FOXP3(+) regulatory T cells has diagnostic and prognostic value as a biomarker for acute graft-versus-host-disease. Biol. Blood Marrow Transplant. 2010, 16:907-914.
18. Jordan K.K., Christensen I.J., Heilmann C., Sengelov H., Muller K.G. Pretransplant C-reactive protein as a prognostic marker in allogeneic stem cell transplantation. Scand. J. Immunol. 2013.
19. Kataoka K., Nannya Y., Hangaishi A., Imai Y., Chiba S., Takahashi T., et al. Influence of pretransplantation serum ferritin on nonrelapse mortality after myeloablative and nonmyeloablative allogeneic hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 2009, 15:195-204.
20. Lv M., Ye H.G., Zhao X.S., Zhao X.Y., Chang Y.J., Liu D.H., et al. Ceruloplasmin is a potential biomarker for aGvHD following allogeneic hematopoietic stem cell transplantation. PLOS ONE 2013, 8:e58735.
21. Wierzbicka D., Gromadzka G. Ceruloplasmin, hephaestin and zyklopen: the three multicopper oxidases important for human iron metabolism. Postepy. Hig. Med. Dosw. 2014, 68:912-924.
22. Cuzzola M., Fiasche M., Iacopino P., Messina G., Martino M., Console G., et al. A molecular and computational diagnostic approach identifies FOXP3, ICOS, CD52 and CASP1 as the most informative biomarkers in acute graft-versus-host disease. Haematologica 2012, 97:1532-1538.
23. Kosmaczewska A., Bilinska M., Ciszak L., Noga L., Pawlak E., Szteblich A., et al. Different patterns of activation markers expression and CD4+ T-cell responses to ex vivo stimulation in patients with clinically quiescent multiple sclerosis (MS). J. Neuroimmunol. 2007, 189:137-146.
24. Fowler D.H., Foley J., Whit-Shan H.J., Odom J., Castro K., Steinberg S.M., et al. Clinical cytokine storm as revealed by monocyte intracellular flow cytometry: correlation of tumor necrosis factor alpha with severe gut graft-versus-host disease. Clin. Gastroenterol. Hepatol. 2004, 2:237-245.
25. Symington F.W., Symington B.E., Liu P.Y., Viguet H., Santhanam U., Sehgal P.B. The relationship of serum IL-6 levels to acute graft-versus-host disease and hepatorenal disease after human bone marrow transplantation. Transplantation 1992, 54:457-462.
26. Antin J.H., Ferrara J.L. Cytokine dysregulation and acute graft-versus-host disease. Blood 1992, 80:2964-2968.